Reata Pharmaceuticals — FY2020 Earnings Presentation
48 slides from Reata Pharmaceuticals's earnings presentation, Mar 1, 2021
Slide 1: 4th Quarter and Full Year 2020 Financial Results and Update on Clinical Development Programs
4th Quarter and Full Year 2020 Financial Results and Update on Clinical Development Programs March 1, 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statement
Slide 3: Today's Agenda
Opening Remarks | Warren Huff, CEO Program Updates | Colin Meyer, MD, Chief R&D Officer Chronic Kidney Disease Pipeline CARDINAL & EAGLE Update FALCON Update MERLIN Update Neurology Pipeline MOXIe Update RTA 901 Update Financial & Operational Update | Manmeet Soni, COO & CFO Concluding Remarks | War
Slide 4: Reata's First NDA Submitted
Reata’s First NDA Submitted Submitted NDA in the U.S. for bardoxolone for treatment of patients with CKD caused by Alport syndrome Includes a request for Priority Review Expect PDUFA date in 4Q21 pending Priority Review Preparing for potential Advisory Committee meeting FDA: U.S. Food and Drug Admin
Slide 5: Reata at a Glance
Reata at a Glance CKD1 Pipeline Submitted Reata’s First NDA for bardoxolone in Alport syndrome Enrolled >220 patients in FALCON, expected enrollment completion in 4Q21 Initiated MERLIN study for patients with CKD at risk of fast progression, data expected 2H21 Neurology Pipeline Submitted Type C mee
Slide 6: Chronic Kidney Disease Pipeline
Chronic Kidney Disease Pipeline
Slide 7: CARDINAL Phase 3 Year 1 Data / EAGLE Year 1 Data
CARDINAL Phase 3 YEAR 2 Data EAGLE Year 3 Data
Slide 8: Alport Syndrome: Second Most Common Hereditary Form of CKD
1Kruegel et al., Nat Rev Nephrol (2013), Gomez et al., JCI (2015); 2Groopman et al. N Engl J Med. 2019; 3CARDINAL Phase 3 historical eGFR decline rate, units of mL/min/1.73 m2 are represented as mL/min throughout this presentation; 4Kashtan et al., Kidney Int (2018), ESKD: end-stage kidney disease;
Slide 9: Data Supporting Bardoxolone Clinical Efficacy and Safety in Alport Syndrome
Data Supporting Bardoxolone Clinical Efficacy and Safety in Alport Syndrome *As of February 25, 2021 9
Slide 10: Clinical Trials Enrolling >3,000 Patients Support Bardoxolone Alport Syndrome NDA
Clinical Trials Enrolling >3,000 Patients Support Bardoxolone Alport Syndrome NDA Improvements in eGFR, measured GFR (inulin clearance), creatinine clearance Reductions in inflammatory biomarkers Sustained eGFR improvements for up to three years Significant increase in off-treatment eGFR after withd
Slide 11: Chronic Inflammation Drives CKD Progression
Chronic Inflammation Drives CKD Progression Nrf2 promotes resolution of inflammation and is suppressed in many forms of CKD Genome-wide analyses validate association between impaired Nrf2 activity and reduced kidney function across nine forms of CKD, including Alport syndrome10 1Cuadrado et al., Nat
Slide 12: Through Activation of Nrf2 Bardoxolone Suppresses Inflammation and Fibrosis and Restores SNGFR
Through Activation of Nrf2 Bardoxolone Suppresses Inflammation and Fibrosis and Restores SNGFR 1Kidokoro et al., ASN (2019); 2Ding et al., Kindey Intertional (2013); 3Aminzadeh et al., Redox Biol (2013); 4Hisamichi et al., Hypertension Res (2018); 5Zoja et al., ASN (2010); 6Nagasu et al., FASEB (201
Slide 13: CARDINAL Phase 3: Pivotal Study Design
CARDINAL Phase 3: Pivotal Study Design International, randomized, double-blind, placebo-controlled, registrational, two-year trial Largest and longest interventional study in patients with AS Enrolled a wide and representative range of patients with AS eGFR: 30 to 90 mL/min Age: 12 to 70 years Prima
Slide 14: CARDINAL Phase 3 Met Year 1 and Year 2 Primary Endpoints
CARDINAL Phase 3 Met Year 1 and Year 2 Primary Endpoints Sustained increases in eGFR vs. placebo observed through 2 years ITT population includes all patients, including those who discontinued mITT population only includes eGFR values for patients who were receiving bardoxolone ITT: intend to treat;
Slide 15: On-Treatment eGFR Benefit Observed Across All Pre-specified Subgroups
On-Treatment eGFR Benefit Observed Across All Pre-specified Subgroups ACE inhibitor: Angiotensin-converting enzyme inhibitor; ARB: Angiotesin II receptor blocker; XLAS: X-linked Alport syndrome 15
Slide 16: CARDINAL Phase 3 Met Year 1 and Year 2 Key Secondary Endpoints
CARDINAL Phase 3 Met Year 1 and Year 2 Key Secondary Endpoints Validate on-treatment change as beneficial and not harmful Bardoxolone slowed rate of irreversible loss of kidney function compared to placebo 16
Slide 17: Off-Treatment eGFR Increase Confirmed in Year 2 and Slopes Demonstrate Slowing of Disease Progression
Off-treatment eGFR Slope Off-Treatment eGFR Increase Confirmed in Year 2 and Slopes Demonstrate Slowing of Disease Progression The key secondary, off-treatment eGFR endpoint was analyzed using analysis of covariance (ANCOVA). The point estimate for each treatment group was based on a model that used
Slide 18: Early Bardoxolone eGFR Increases in CARDINAL Predictive of Year 2 Response
Quartile Analysis by Week 12 eGFR Change: Highest responders at Week 12 have highest Week 100 and Week 104 changes in eGFR Not associated with accelerated progression of kidney disease Opposite pattern than hyperfiltration Early Bardoxolone eGFR Increases in CARDINAL Predictive of Year 2 Response SD
Slide 19: Largest Treatment Effect Observed in Pediatric Patients
eGFR Change from Baseline Mean± SEM, mL/min/1.73 m2 Placebo (n=12) Bardoxolone (n=11) p=0.004 p=0.017 Mean ± SEM eGFR Change (mL/min) Pediatric patients have most severe mutations and fastest rate of progression Two-year duration represents ~30% of remaining dialysis-free time Largest Treatment Effe
Slide 20: Pediatric Data Demonstrate eGFR Increases Not Associated with Glomerular Injury
Across all patients, UACR not significantly different than placebo at Weeks 100 and 104 In pediatric placebo patients, progression of UACR observed over two years UACR not worsened by bardoxolone and decreased relative to placebo Fold-Change in UACR Over Time in Pediatric Patients UACR: urine albumi
Slide 21: Bardoxolone Profile is Novel and Differs from Hyperfiltration
Bardoxolone Profile is Novel and Differs from Hyperfiltration 21 1Wright et. Al., JAMA (2002); 2Kidokoro et al., ASN (2019); 3Aminzadeh et al., Xenobiotica (2014); 4CARDINAL Phase 3 data; 5EAGLE data
Slide 22: Nonclinical Data Supporting Aminotransferase Increases Are Pharmacological Effect Due to Nrf2 Activation
Aminotransferases widely expressed in multiple tissues Aminotransferase activity influenced by Nrf2 status Bardoxolone increases aminotransferase expression in multiple tissue types Serum ALT Activity Hepatic mRNA Kidney mRNA Liver (SK-HEP-1) Liver (HepG2) Colon (HT-29) Kidney (NRK-52E) Macrophages
Slide 23: Aminotransferase Increases Associated with Reductions in Total Bilirubin
Profile of transient, reversible aminotransferase increases consistent with prior trials, including no cases of Hy’s Law Elevations believed to be related to pharmacology of drug and not consistent with clinical evidence of liver injury Protocol-required discontinuations (n=6) due to conservative ma
Slide 24: Decreases in Body Weight not Associated with Changes in eGFR
Off-Treatment Off-Treatment Decreases in weight observed with bardoxolone that were more pronounced in patients with higher baseline BMI Changes in weight not correlated with changes in eGFR with bardoxolone (r = -0.07; p = 0.7) eGFR increases with bardoxolone not due to loss of muscle mass but refl
Slide 25: Alport Syndrome Program Conclusions
cycle Alport syndrome is a rare, severe disease with no approved therapies Primary and key secondary efficacy endpoints were met at Year 1 and Year 2 CARDINAL was the largest interventional trial conducted in patients with Alport syndrome Disease modifying profile Comprehensive safety database in >3
Slide 26: Bardoxolone in ADPKD
Bardoxolone in ADPKD
Slide 27: ADPKD: Most Common Hereditary Form of CKD
1Bergmann et al. Nat Rev Dis Primers. 2018; 2Podrini et al. Cell Signal. 2020; 3NIH – About Autosomal Dominant Polycystic Kidney Disease (link), Willey et.al Kidney Dis 2019; 4Torres et al. N Engl J Med. 2017, Rastogi et al. Ther Clin Risk Manag. 2019; 5What is ADPKD? Polycystic Kidney Disease Found
Slide 28: FALCON Phase 3 Study of Bardoxolone in ADPKD
FALCON Phase 3 Study of Bardoxolone in ADPKD Phase 3 similar in design to CARDINAL with two-year treatment duration Planning to enroll 550 patients across approximately 100 sites in the U.S., Europe, Australia, and Japan eGFR 30-90 mL/min Age 18-70 years old Key primary endpoint: off-treatment c
Slide 29: Bardoxolone in Patients with CKD at Risk of Rapid Progression
Bardoxolone in Patients with CKD at Risk of Rapid Progression
Slide 30: MERLIN Phase 2 Study of Bardoxolone in Patients with CKD at Risk for Rapid Progression
MERLIN Phase 2 Study of Bardoxolone in Patients with CKD at Risk for Rapid Progression Proof of concept, Phase 2 trial to evaluate the safety and efficacy of bardoxolone in patients at risk of rapidly progressing CKD due to multiple etiologies Multi-center, double-blind, placebo-controlled Planning
Slide 31: Neurology Pipeline
Slide 32: Omaveloxolone in Friedreich's Ataxia
Omaveloxolone in Friedreich’s Ataxia
Slide 33: Friedreich's Ataxia: No Approved Therapy
1Cook and Giunti, Br. Med. Bull. 2017; 2Patel et. al. Ann. Clin. Transl. Neurol. 2016 Friedreich’s Ataxia: No Approved Therapy 33
Slide 34: Omaveloxolone Regulatory Update
Omaveloxolone Regulatory Update After review of the MOXIe Part 2 data, FDA recommended additional analyses to increase the persuasiveness of the findings Treatment-naïve patients from MOXIe Part 1 and Part 2 served as their own controls to assess changes in mFARS in MOXIe Extension in the Baseline-C
Slide 35: Delayed-Start Analyses Support Disease-Modifying Profile
mFARS: modified Friedreich’s ataxia rating scale; PBO: placebo; Omav: omaveloxolone Delayed-Start Analyses Support Disease-Modifying Profile Data from the MOXIe extension study were analyzed as “Delayed-Start” analyses Comparison of mFARS during the open-label MOXIe extension for patients randomized
Slide 36: Omaveloxolone Next Steps
Requested Type C meeting with FDA to discuss Delayed-Start Analyses Friedreich’s ataxia development program Plan to initiate a second pivotal study in 2H21, following discussions with FDA and EMA Omaveloxolone Next Steps EMA: European Medicines Agency 36
Slide 37: Omaveloxolone Pharmacology May Be Applicable to a Broad Set of Neurological Diseases
Omaveloxolone Pharmacology May Be Applicable to a Broad Set of Neurological Diseases Yang et al., PLoS One (2009); Neymotin et al., Free Rad Bio (2011); Dinkova-Kostova et al., (2015); Stack et al., Free Rad Biol Med 49 (2010); Dumont et al., J Neurochem (2009); Kim et al., Cells (2019); Shekh-Ahmad
Slide 38: RTA 901 Hsp90 Modulator for Diabetic Neuropathy
RTA 901 Hsp90 Modulator for Diabetic Neuropathy
Slide 39: RTA 901: Hsp90 Modulator for Diabetic Peripheral Neuropathic Pain
RTA 901: Hsp90 Modulator for Diabetic Peripheral Neuropathic Pain RTA 901 is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90 Binding at the C-terminus of Hsp90 disrupts Hsp90-HSF1 complex and leads to increased transcription of Hsp70, a cytoprotective and molecular
Slide 40: RTA 901 Rapidly Reverses Hyperalgesia and Insensate Neuropathy in Animal Models
RTA 901 Rapidly Reverses Hyperalgesia and Insensate Neuropathy in Animal Models RTA 901 treatment in rat model of type 1 diabetic neuropathic pain demonstrated dose-dependent, sustained suppression of hypersensitivity a day after initiation of treatment RTA 901 treatment reverses loss of sensation i
Slide 41: Phase 2 Study in Diabetic Peripheral Neuropathic Pain Planned for 4Q21
Phase 2 Study in Diabetic Peripheral Neuropathic Pain Planned for 4Q21 Approximately 4 million patients in the U.S. are affected with moderate or severe diabetic peripheral neuropathic pain (DPNP)1-3 Estimated 2 million adult patients diagnosed with DPNP seek treatment annually2 Approximately half o
Slide 42: Operations, Financials, Intellectual Property
Operations, Financials, Intellectual Property
Slide 43: Financial Summary
Financial Summary 2020 Year End Cash & Shares Cash $818.2M Total Shares Outstanding 36.1M 31.1M class A shares outstanding 5.0M class B shares outstanding 1Non-GAAP operating expenses exclude stock-based compensation expenses; 2Non-GAAP net loss excludes stock-based compensation expenses, non-cash i
Slide 44: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures 44
Slide 45: Preparation for Launch Success
Disease Awareness Market Research Product Access & Health Economics Operational Readiness Reata has all necessary people, processes and systems in place to support a successful launch Preparation for Launch Success 2021 Commercial Readiness Goals Physicians, patients, and payers recognize AS, burden
Slide 46: Concluding Remarks
—<— Concluding Remarks
Slide 47: Key 2021 Goals
Key 2021 Goals BARDOXOLONE FOR CHRONIC KIDNEY DISEASE NDA submitted requesting Priority Review = NDA accepted and filed by FDA Alport Syndrome CARDINAL Expected PDUFA if designated as Priority Review Submit MAA to EMA Continued FALCON enrollment ADPKD a Complete FALCON enrollment wv. At Risk of Init
Slide 48: Q & A
Q & A